Pembrolizumab lenvatinib in metastatic uterine carcinosarcoma cohort: safety and efficacy from the french multicenter early access program subgroup (LARENA study)
2026 · International Journal of Gynecological Cancer · 0 citations
https://doi.org/10.1016/j.ijgc.2025.103032